西班牙裔肺癌患者的体细胞突变与祖先标志物
该回顾性观察研究对163例西班牙裔/拉丁裔肺癌患者肿瘤DNA行靶向外显子测序及祖先分析,并与非西班牙裔白人队列比较。西班牙裔腺癌患者EGFR突变频率31%高于非西班牙裔白人的17%(p<0.001),KRAS突变频率较低(20% vs 38%,p=0.002),TP53突变频率相似(46% vs 40%,p=0.355)。作者结论认为西班牙裔肺腺癌驱动突变频率与非西班牙裔白人不同,与其美洲原住民祖先相关,需进一步评估该人群驱动突变谱。
要点
- 西班牙裔肺腺癌EGFR突变频率31%,高于非西班牙裔白人的17%(p<0.001)。
- KRAS突变频率西班牙裔20%低于非西班牙裔白人38%(p=0.002)。
- TP53突变频率两组相似(46% vs 40%,p=0.355),但受祖先影响(p=0.009)。
核心结论
- 西班牙裔肺癌患者的驱动突变频率与非西班牙裔白人患者不同,且与其美洲原住民祖先相关。
- 西班牙裔人群的驱动突变谱需进一步评估。
研究设计与样本
- 回顾性观察研究,纳入163例西班牙裔/拉丁裔肺癌患者的肿瘤样本。
- 对肿瘤DNA行靶向外显子测序(>1000个基因,包括EGFR、KRAS、STK11和TP53)及祖先分析。
- 将西班牙裔队列突变频率与相似的非西班牙裔白人对队列比较,并与祖先、性别、吸烟状态和肿瘤组织学类型做相关性分析。
主要发现
- 西班牙裔队列腺癌患者(n=120)中31%有EGFR突变,非西班牙裔白人对队列为17%(p<0.001)。
- KRAS突变频率西班牙裔为20%,非西班牙裔白人为38%(p=0.002)。
- STK11突变频率西班牙裔为8%,非西班牙裔白人为16%(p=0.065)。
- TP53突变频率西班牙裔为46%,非西班牙裔白人为40%(p=0.355)。
- 在西班牙裔队列内,祖先影响TP53突变率(p=0.009),并可能影响EGFR、KRAS和STK11突变率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To address the lack of genomic data from Hispanic/Latino (H/L) patients with lung cancer, the Latino Lung Cancer Registry was established to collect patient data and biospecimens from H/L patients. METHODS: This retrospective observational study examined lung cancer tumor samples from 163 H/L patients, and tumor-derived DNA was subjected to targeted-exome sequencing (>1000 genes, including EGFR, KRAS, serine/threonine kinase 11 gene [STK11], and tumor protein p53 gene [TP53]) and ancestry analysis. Mutation frequencies in this H/L cohort were compared with those in a similar cohort of non-Hispanic white (NHW) patients and correlated with ancestry, sex, smoking status, and tumor histologic type. RESULTS: Of the adenocarcinomas in the H/L cohort (n = 120), 31% had EGFR mutations, versus 17% in the NHW control group (p < 0.001). KRAS (20% versus 38% [p = 0.002]) and STK11 (8% versus 16% [p = 0.065]) mutations occurred at lower frequency, and mutations in TP53 occurred at similar frequency (46% versus 40% [p = 0.355]) in H/L and NHW patients, respectively. Within the Hispanic cohort, ancestry influenced the rate of TP53 mutations (p = 0.009) and may have influenced the rate of EGFR, KRAS, and STK11 mutations. CONCLUSIONS: Driver mutations in H/L patients with lung adenocarcinoma differ in frequency from those in NHW patients associated with their indigenous American ancestry. The spectrum of driver mutations needs to be further assessed in the H/L population.
引用
- Gimbrone NT, Sarcar B, Gordian ER, et al. Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients. J Thorac Oncol. 2017. PMID: 28911955. doi:10.1016/j.jtho.2017.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。